| 2 | 1/1 | 返回列表 |
| 查看: 429 | 回復: 1 | |||
| 本帖產(chǎn)生 1 個 翻譯EPI ,點擊這里進行查看 | |||
[求助]
求一段論文翻譯,因本人是學俄語的,應該挺簡單的,謝謝
|
|||
|
How important coadministration of antiplatelet agents is in the pathogenesis of some of these hemorrhagic events is unclear in the context of uremic platelet dysfunction. Antiplatelet agents were administered to 7 of our 10 patients and 1 of the 5 cases described. However, their use would not explain the prolonged APTT seen in 7 of our 10 cases. Four of our patients were on the maintenance hemodialysis program; although the onset of bleeding was on nondialysis days in all patients and the quoted APTTs were 48 hours after hemodialysis, the possible contribution of heparin during dialysis treatment remains unclear. Finally, in our case series, 7 of 10 patients had end-stage renal disease (ESRD), but 1 patient had a CrCl of 30 mL/min (0.50 mL/s) and still experienced a major hemorrhagic event (Fig1). Although there was an overlap with warfarin therapy, he had only been administered 2 doses,and his international normalized ratio was 2.4. LMWHs are derived from standard UFH through controlled chemical or enzymatic degradation, resulting in heterogeneous molecules with individual pharmacological properties. Each commercial product is considered by theWorld Health Organization as a distinct and noninterchangeable drug. There are important differences between LMWHs and UFH, but the clinical relevance of their differences in terms of effectiveness or safety remains unclear. Hence, LMWHs have a reduced ability to catalyze the inhibition of thrombin (IIa), whereas they retain the ability to inhibit Xa activity. The reduced binding of LMWH to plasma proteins and cells (including platelets, endothelial cells, and macrophages) contributes to its more predictable dose response and longer plasma half-life. LMWHs are eliminated primarily by the kidney through glomerular filtration in comparison to UFH, in which renal clearance becomes an important route of elimination only at greater concentrations. |
木蟲 (著名寫手)
| 在尿毒性血小板功能異常下,多種抗血小板藥物聯(lián)用對一些失血事件的病理進程有何重要意義,尚不清楚?寡“逅幬镉糜谒龅10個病人中的7個,以及5個病例中的一個。然而,這些藥物的使用不能解釋我們在10個病例中的7個中觀察到的APTT的延長。我們的4個病人曾在接受維持性血液透析;雖然所有病人滲血的開始是在非透析日,且采用的APTTs值是透析48小時后的值,透析治療中肝素的可能貢獻尚不清楚。最后,在我們的病例系列里,10個病人中的7個患有終末期腎臟病,但是其中1個病人的CrCl值為30 mL/min (0.50 mL/s),仍然經(jīng)歷了大出血事件(圖1)。盡管和華法林抗凝治療存在一定的重疊,該病人僅使用了2劑量,他的國際標準化比率為2.4。LMWHs源自化學降解或酶降解的標準UFH,導致異質(zhì)分子具有各自的藥學特性。每個商業(yè)產(chǎn)品都被世界衛(wèi)生組織認為是獨特的不可相互替換的藥物。LMWHs 和 UFH有著重要區(qū)別,但是就療效或安全性而言,它們這些區(qū)別的臨床相關性仍不清楚。因此, LMWHs抑制凝血酶 (IIa)的催化能力降低了,但是仍然保持其抑制Xa活性的能力。LMWH和血漿蛋白及細胞(包括血小板、內(nèi)皮細胞和巨噬細胞)的結(jié)合力降低,其劑量反應具有更好的可預測性,并能延長血漿半衰期。與UFH 相比,LMWHs主要由腎通過腎小球濾過去除,UFH只有在較高濃度時,腎清除才是一條重要的清除途徑。 |

| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0703本科鄭州大學求調(diào)劑 +3 | nhj_ 2026-03-25 | 3/150 |
|
|---|---|---|---|---|
|
[考研] 286求調(diào)劑 +12 | PolarBear11 2026-03-26 | 12/600 |
|
|
[考研] 081200-314 +3 | LILIQQ 2026-03-27 | 4/200 |
|
|
[考研] 張芳銘-中國農(nóng)業(yè)大學-環(huán)境工程專碩-298 +4 | 手機用戶 2026-03-26 | 4/200 |
|
|
[考研] 275求調(diào)劑 +10 | jjjjjjjjjjl 2026-03-27 | 10/500 |
|
|
[考研] 0703化學求調(diào)劑,各位老師看看我。! +5 | 祁祺祺 2026-03-25 | 5/250 |
|
|
[考研] 一志愿北京化工大學材料與化工 264分各科過A區(qū)國家線 +10 | 哈哈157349 2026-03-21 | 10/500 |
|
|
[考研] 316求調(diào)劑 +5 | Pigcasso 2026-03-24 | 5/250 |
|
|
[考研] 0703化學338求調(diào)劑! +6 | Zuhui0306 2026-03-26 | 7/350 |
|
|
[考研] 324求調(diào)劑 +5 | hanamiko 2026-03-26 | 5/250 |
|
|
[考研] 276求調(diào)劑。有半年電池和半年高分子實習經(jīng)歷 +10 | 材料學257求調(diào)劑 2026-03-23 | 11/550 |
|
|
[考研] 316求調(diào)劑 +5 | 江辭666 2026-03-26 | 5/250 |
|
|
[考研] 329求調(diào)劑 +5 | 1() 2026-03-22 | 5/250 |
|
|
[考研] 生物學 296 求調(diào)劑 +4 | 朵朵- 2026-03-26 | 6/300 |
|
|
[考研] 中國科學院深圳先進技術研究院-光纖傳感課題組招生-中國科學院大學、深圳理工大學聯(lián)培 +5 | YangTyu1 2026-03-26 | 5/250 |
|
|
[考研] 材料與化工304求B區(qū)調(diào)劑 +3 | 邱gl 2026-03-26 | 6/300 |
|
|
[考研] 352求調(diào)劑 +4 | 大米飯! 2026-03-22 | 4/200 |
|
|
[考研] 299求調(diào)劑 +4 | 15188958825 2026-03-25 | 4/200 |
|
|
[考研] 0703化學調(diào)劑,求導師收 +7 | 天天好運來上岸?/a> 2026-03-24 | 7/350 |
|
|
[考研] 275求調(diào)劑 +6 | shansx 2026-03-22 | 8/400 |
|